A stydy to evaluate the efficacy of EAC-EAM regimen for Helicobacter pylori eradication.
- Conditions
- Helicobacter pylori infection
- Registration Number
- JPRN-UMIN000010803
- Lead Sponsor
- Heiwadai clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
1) Patients with symptoms of hypersensitivity to the study drugs. 2) Patients with a history of H.pylori eradication. 3) Patients with a history of resection of gastrointestinal tract or vagal neurotomy. 4) Patients having peptic ulcer of stages other than the scarred stage as a complication. 5) Patients with warning findings such as vomiting and sudden weight loss. 6) Patients for whom participation in this study is difficult becaese of such complication as serious hepatic disease, renal disease, or cardiac disease. 7) Patients who have received PPI, histamin H2 receptor antagonist, selective muscarine receptor antagonist, anticholinergic drug, antacid, prostaglandin preparation, drug for reinforcing gastric mucosa protection factor, and bismuth preparation within 2 weeks before the diagnosis of H.pylori infection. 8) Women hwo are pregnant, lactating or who may be pregnant. 9) Patients for whom administration of any of following drugs is necessary. Atazanavir sulfate, pimozide, ergotamine or preparation containing ergotamine, tadalafil, SU, and colchicine. 10) Patients who are deemed ineligible as the subjects of study by the principal investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The overall eradication rate
- Secondary Outcome Measures
Name Time Method H,pylori eradication rate by each regimen. H,pylori eradication rate by each factor including CYP2C19 genotype, drug-resistant bacteria, and any other backgrounds. Safety will be investigated on the basis of evaluation of adverse events.